💨 Abstract

Arcturus Therapeutics reported a $9.2 million loss for its second quarter, beating Wall Street's expectations of a higher loss per share. The company generated $28.3 million in revenue. Shares have decreased 33% since January and 37% over the past year, closing at $11.39.

Courtesy: WTOP Staff